Artal Group S.A. I Mab Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	BUY	$45.28 - $74.5 $1.13 Million - $1.86 Million	25,000 Added 3.03%	850,000 $40.3 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $4.29 Million - $6.33 Million	75,000 Added 10.0%	825,000 $59.8 Million
Q1 2021 May 14, 2021	BUY	$44.38 - $63.97 $1.11 Million - $1.6 Million	25,000 Added 3.45%	750,000 $36.4 Million
Q3 2020 Nov 13, 2020	BUY	$27.46 - $47.03 $11 Million - $18.9 Million	401,000 Added 123.77%	725,000 $34.1 Million
Q2 2020 Aug 14, 2020	SELL	$13.0 - $31.0 $338,000 - $806,000	-26,000 Reduced 7.43%	324,000 $9.7 Million
Q1 2020 May 14, 2020	BUY	$10.63 - $15.37 $3.72 Million - $5.38 Million	350,000 New	350,000 $4.55 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.